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Dear Editor, 
The diagnosis of malignant melanoma accounts 
for 1-2% of all cancer diagnoses, around 4% of all 
malignant skin diseases, and 80% of all skin cancer 
deaths (1). The prognosis depends on several factors 
including tumor size, Clark level, Breslow thickness, 
location, ulceration, and presence of metastases. 
Detection of lymph node metastasis is initially ac-
complished by clinical examination and by operative 
evaluation for occult metastasis using sentinel lymph 
node biopsy (SLNB) when indicated (2). Lymph nodes 
(LN) with melanoma metastasis may appear normal 
in early stages, but eventually they become dark, 
firm, and enlarged (3).
In 2017, a 32-year-old female patient was referred 
to our ward by a dermatologist following a biopsy ex-
cision of a nevus under her right breast that tested 
positive for a cutaneous melanoma grade T2aNx with 
a Breslow thickness of 1.9 mm, with no sign of ulcer-
ation and no history of previous illnesses or chronic 
diseases. Based on the American Joint Committee on 
Cancer (AJCC) guidelines, wide excision with a senti-
nel lymph node (SLN) biopsy was indicated (4). The 
patient was injected with 0.4 mL CiTc 99m Nanocoll 
in all four quadrants around the primary scar. A 2 cm 
wide elliptical excision was performed circumferen-
tially around the scar and to the depth of the mus-
cular fascia of the thorax. With the aid of a gamma 
probe, a single radioisotope positive lymph node was 
located in the ipsilateral axilla, but 5 dark pigmented 
lymph nodes situated behind the SLN were visualized 
during manual dissection and thought to be consis-
tent with metastatic disease (Figure 1). Due to this 
new finding, an excisional biopsy of all pigmented 
nodes was performed. Histology of the excised skin 
did not demonstrate any further cancerous cells. 
The size of the SLN was 15 mm, and immunohis-
tochemistry for Melan A was negative for metastatic 
melanoma. Histological analysis of the darkly pig-
mented nodes was negative for metastatic melanoma 
as the pigment was demonstrated to originate from 
the dermal tattoo on the patient’s back that had been 
removed by dermabrasion 3 years before melanoma 
development (Figure 2, Figure 3). 
Figure1. Darkly colored lymph node within the adipose 
tissue.
Figure 2. Histopathology demonstrated tattoo pigment 
within the regional lymph nodes (hematoxylin and eosin 
×10).
Figure 3. Histopathology demonstrated tattoo pigment 
within the regional lymph nodes (hematoxylin and eosin 
×40).
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Dermal tattooing results in initial sloughing of 
the overlying epidermis, variable dermal inflamma-
tion, and gradual assimilation of pigment into mac-
rophages. Much of the pigment is rapidly carried into 
regional draining LN, which was shown in 2010 on a 
SKH-1a mouse model, and causes lymphadenopathy 
which is thought to be a result of local inflammation 
(6). Importantly, even after removal of the offend-
ing cutaneous tattoo the tattoo pigment can persist 
in draining or distant nodes visible to the naked eye 
(7). In such cases, LN can mimic metastatic malignant 
melanoma and may prompt the surgeon to proceed 
with radical lymph node dissection which may not be 
necessary. 
Despite clear guidelines for melanoma treatment 
in the general population, there are several questions 
that need to be addressed: firstly, how should a phy-
sician approach a patient with unknown history of 
tattoo removal, a diagnosis of melanoma, and intra-
operative darkly pigmented lymph nodes? Secondly, 
due to the lack of scientific data and treatment proto-
col, if the SLN is normally colored while other regional 
nodes are darkly pigmented, what should the treat-
ment plan entail?
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